Abstract Library

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4575 Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase II, randomised, parallel-group study

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for the treatment of carcinoid syndrome (CS).

Conference:

Presenting Author: Hajac L

Authors: Hajac L, Chauhan A, Mohamed A, Usiskin K, Mui C,

Keywords: paltusotine, phase 2 trial, somatostatin receptor agonist, safety, carcinoid syndrome,

#3871 A phase 2, randomized, parallel-group study to evaluate the safety, pharmacokinetics, and dose response of paltusotine treatment in patients with carcinoid syndrome

Introduction: While long-acting somatostatin receptor ligands (SRLs) are mainstay treatments for carcinoid syndrome (CS), symptom relief at labelled doses is inadequate for many patients. Paltusotine is a novel oral, nonpeptide, selective somatostatin receptor type 2 agonist. In patients with acromegaly, paltusotine maintains plasma IGF-1 levels in patients switching from long-acting SRLs. Paltusotine was well tolerated in phase 2 acromegaly studies.

Conference:

Presenting Author:

Authors: Chauhan A, Shaheen S, Usiskin K, Odueyungbo A, Mui C,

Keywords: Paltusotine, Phase 2 trial, Somatostatin receptor agonist, Safety, Pharmacokinetics, Carcinoid syndrome,

#3018 Real-Life Data for Telotristat Ethyl in Resistant-to-Treatment Carcinoid Syndrome: Is It Efficacious in Carcinoid Flushing as Well?

Introduction: Results from clinical trials with telotristat ethyl (TE) are really encouraging about its role in carcinoid syndrome-associated diarrhoea, however, its efficacy in flushing has been equivocal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Gertner J

Authors: Gertner J, Eastwood O, Furtado O'Mahony L, Quaglia E, McSweeney A,

Keywords: telotristat,

#2262 Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome

Introduction: Telotristat ethyl (TE) is a treatment for carcinoid syndrome (CS) diarrhea used in combination with somatostatin analog (SSA) therapy. In the Phase 3, randomized, placebo-controlled, double-blind TELESTAR and TELECAST studies, CS patients received TE at 250 mg 3 times per day (tid), 500 mg tid, or placebo tid in addition to SSAs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Dillon J, Kulke M, Warner R, Bergsland E, Welin S,

Keywords: telotristat ethyl, somatostatin analogs, carcinoid syndrome,